Abstract
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the "targeted therapies", particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols
-
Bevacizumab
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Clinical Trials as Topic
-
Congresses as Topic
-
Humans
-
Indoles / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Protein Kinases / drug effects
-
Pyrroles / therapeutic use
-
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
-
Sirolimus / analogs & derivatives
-
Sirolimus / pharmacology
-
Sirolimus / therapeutic use
-
Sunitinib
-
TOR Serine-Threonine Kinases
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Indoles
-
Protein Kinase Inhibitors
-
Pyrroles
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
temsirolimus
-
Protein Kinases
-
MTOR protein, human
-
Receptors, Platelet-Derived Growth Factor
-
TOR Serine-Threonine Kinases
-
Sunitinib
-
Sirolimus